Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00606541 · ClinicalTrials.gov registry record · Early Phase 1
An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)
A Early Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 55
- Enrollment target
NCT00606541: Clinical Trial Early Phase 1 study, sponsored by Duke University.
NCT00606541 is a Early Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 55 participants, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00606541, a Early Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.
Interventions
- DRUG Placebo
- DRUG Quetiapine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-11 |
| Phase | Early Phase 1 |
Why NCT00606541 stopped before completion
NCT00606541 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, roughly in line with the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00606541 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00606541 about?
NCT00606541 is a clinical study titled "An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)". Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.
What is the current status of trial NCT00606541?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 55 participants. The study started on 2008-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00606541?
The interventions under investigation include: Placebo (DRUG), Quetiapine XR (DRUG).
Who is sponsoring clinical trial NCT00606541?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00606541's enrollment target sits among peer trials
55 458th of 2000 higher than 1,537 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia